The Beacon trial enrolled 31 patients, randomizing them at a rate of 3:2:2 to receive a daily 45-mg oral dose of brepocitinib ...
Zacks Investment Research on MSN
Pfizer bets big on obesity and oncology with 2026 pipeline push
In 2025, Pfizer PFE upped its efforts to rebuild its pipeline through acquisitions. Pfizer invested around $9 billion in M&A ...
Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.
Pfizer made one thing clear this week: It's officially back in the obesity race.
Priovant Therapeutics, a company established in 2021 as part of a transaction between Pfizer (PFE) and Roivant Sciences (ROIV), announced positive mid-stage trial results for its lead asset, ...
Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on ...
In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a ...
Pfizer reported weight-loss results for a monthly GLP-1 obesity injection that it acquired as part of the $10 billion Metsera ...
Pfizer reported that its newly acquired weight loss drug showed promise as a monthly treatment, though the field is growing ...
PFE stock today: Pfizer's stock dipped despite strong fourth-quarter earnings. Investors reacted to the company's modest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results